Critical

Antepartum haemorrhage (APH) — placenta praevia & placental abruption

Bleeding >= 24 weeks gestation from/into the genital tract; two main life threats: placenta praevia (low-lying placenta) and placental abruption (premature separation). DRAFT for clinician review. · Obstetric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

APH = bleeding from or into the genital tract at >= 24+0 weeks before birth. Praevia: painless, unprovoked bleed, soft non-tender uterus, often malpresentation; confirmed on scan. Abruption: painful bleed (may be concealed with little visible blood), tender/woody hard uterus, fetal distress, DIC risk disproportionate to visible loss. Also consider vasa praevia (painless bleed + acute fetal compromise at membrane rupture) and local/uterine causes. Maternal shock may be underestimated in concealed abruption and in young fit women who compensate until sudden collapse. Avoid vaginal/digital examination until praevia excluded by ultrasound.

Red flags

  • Maternal shock, tachycardia, rising shock index (loss often concealed in abruption)
  • Woody-hard, tender uterus; pain out of proportion to visible bleeding
  • Abnormal CTG / fetal bradycardia / absent fetal heart (fetal death)
  • Sudden fetal compromise at membrane rupture + painless bleed = vasa praevia
  • Falling fibrinogen / coagulopathy / DIC
  • Scar pain + bleeding + maternal collapse = uterine rupture
  • Recurrent small 'herald' bleeds in known praevia

Assessment

Differential diagnosis

  • Placenta praevia / low-lying placenta
  • Placental abruption (revealed or concealed)
  • Vasa praevia (fetal haemorrhage)
  • Uterine rupture (esp. prior CS/scar)
  • Marginal/circumvallate placenta, 'show'/labour
  • Local causes: cervical ectropion, polyp, cervical cancer, trauma, infection
  • Bloody show of labour

Investigations

  • Maternal obs + shock index; continuous CTG once stable (fetal viability/distress)
  • FBC, group & save + crossmatch (2-4 units), coagulation/fibrinogen, U&E, LFT
  • Kleihauer (Rh-negative women: quantify feto-maternal haemorrhage & anti-D dose)
  • Fibrinogen is the best early marker of abruption severity/DIC — a low or falling level is ominous
  • Transabdominal + transvaginal ultrasound for placental site (praevia); scan is poor for abruption (clinical diagnosis)
  • Speculum (only once praevia excluded) to assess cervix/local cause; AVOID digital VE until praevia excluded
  • Catheterise + hourly urine output; CTG/ultrasound for fetal wellbeing
  • Cross-check Rh/antibody status

Management

  • Call for help early: senior obstetrician, anaesthetist, midwife, neonatal team, blood bank — activate major obstetric haemorrhage protocol if shocked
  • Resuscitate mother first (maternal resus = best fetal resus): 2 large-bore IV cannulae, left lateral tilt / manual uterine displacement, high-flow O2, warmed crystalloid then blood
  • Do NOT perform digital vaginal examination until placenta praevia excluded by ultrasound
  • Group-specific/O-neg blood if exsanguinating; activate massive transfusion with 1:1:1 ratio, give fibrinogen/cryoprecipitate guided by levels (target fibrinogen > 2 g/L)
  • Give tranexamic acid 1 g IV early in significant haemorrhage
  • Anti-D immunoglobulin for all Rh-negative women with APH (dose adjusted by Kleihauer)
  • Antenatal corticosteroids if 24-34+6 weeks and preterm birth anticipated; MgSO4 for neuroprotection if < 30 (consider 30-33+6) weeks
  • Decide delivery: maternal instability, fetal distress, or significant abruption at viable gestation -> emergency caesarean (or vaginal if advanced labour and stable). Expectant management only if minor bleed, stable mother, reassuring fetus, preterm
  • Continuous fetal monitoring; prepare theatre; keep NBM

Drugs & doses

Tranexamic acid 1 g IV over 10 min, repeat after 30 min if bleeding continues (pregnancy-safe; give early)
Anti-D immunoglobulin: Rh-negative + sensitising event — 500 IU IM (dose per Kleihauer); give within 72 h [verify local dose]
Betamethasone 12 mg IM, 2 doses 24 h apart (or Dexamethasone 6 mg IM 12-hourly x 4) if 24-34+6 weeks (antenatal corticosteroids)
Magnesium sulfate 4 g IV loading over 20-30 min then 1 g/h infusion for fetal neuroprotection if birth < 30 weeks expected (consider 30-33+6) [verify local protocol]
Oxytocin 5 IU IV slow + 40 IU infusion post-delivery to prevent PPH (abruption/praevia raise PPH risk)
Packed red cells / FFP / platelets / cryoprecipitate per massive transfusion protocol; target fibrinogen > 2 g/L, platelets > 50
Rho(D): if large feto-maternal haemorrhage on Kleihauer, additional anti-D required [verify local dose]

Disposition

Admit all APH to labour ward/obstetric HDU with continuous fetal + maternal monitoring. Emergency theatre for instability, fetal distress or significant abruption. Minor praevia bleed, stable, preterm: admit for expectant management, steroids, inpatient or supervised outpatient care with clear delivery plan; crossmatch available. Senior obstetric + anaesthetic + neonatal involvement; alert blood bank.

Complications & pitfalls

  • Hypovolaemic shock, DIC, acute kidney injury (acute tubular/cortical necrosis)
  • Couvelaire uterus, postpartum haemorrhage, hysterectomy
  • Fetal hypoxia, growth restriction, stillbirth, prematurity
  • Amniotic fluid embolism, maternal death
  • Sheehan syndrome (pituitary necrosis) after massive haemorrhage
  • Rhesus isoimmunisation if anti-D omitted

Exam pearls

  • Maternal resuscitation is the best fetal resuscitation — stabilise mother first.
  • Concealed abruption: visible blood poorly reflects true loss; trust shock index and uterine signs.
  • Never do a digital VE in APH until praevia is excluded on ultrasound.
  • Fibrinogen falls early and fastest in abruption — use it to gauge severity and guide cryoprecipitate.
  • Every Rh-negative woman with APH needs anti-D (Kleihauer-adjusted) within 72 h.
  • Painless bleed + fetal compromise at ROM = think vasa praevia (fetal, not maternal, blood).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.